Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma

European Respiratory Journal

Volumn 24, Issue 6, 2004, Pages 932-937

  Petersen, R ^a   Agertoft, L ^a   Pedersen, S ^a  

^a KOLDING HOSPITAL   (Denmark)

Author keywords

Asthma; Children; Dose response; Exercise; Hydrofluoroalkane beclomethasone dipropionate; Nitric oxide

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FLUORINATED HYDROCARBON; NITRIC OXIDE; PLACEBO;

ADOLESCENT; AEROSOL; ARTICLE; ASTHMA; BRONCHOSPASM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EXERCISE INDUCED ASTHMA; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADOLESCENT; AEROSOL PROPELLANTS; AEROSOLS; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; ASTHMA, EXERCISE-INDUCED; BECLOMETHASONE; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DENMARK; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCARBONS, FLUORINATED; MALE; NITRIC OXIDE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 10444247396     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00141303     Document Type: Article

References (30)

1. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995; 95: 29-33.
2. Jonasson G, Carlsen K-H, Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J 1998; 12: 1099-1104.
3. Jonasson G, Carlsen K-H, Hultquist C. Low-dose budesonide improves exercise-induced bronchospasm in school-children. Pediatr Allergy Immunol 2000; 11: 120-125.
4. Jonasson G, Carlsen K-H, Jonasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000; 55: 740-748.
5. Hofstra WB, Neijens HJ, Duiverman EJ, et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000; 29: 415-423.
6. Waalkens HJ, van Essen-Zandvliet EE, Gerritsen J, Duiverman EJ, Kerrebijn KF, Knol K. The effect of an inhaled corticosteroid (budesonide) on exercise-induced asthma in children. Dutch CNSLD Study Group. Eur Respir J 1993; 6: 614-616.
7. Vidal C, Fernandez-Ovide E, Pineiro J, Nunez R, Gonzalez-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2001; 86: 655-658.
8. Vathenen AS, Knox AJ, Wisniewski A, Tatersfield AE. Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air -hyperventilation in patients with asthma. Thorax 1991; 46: 811-816.
9. Freezer NJ, Croasdell H, Doull IJ, Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Eur Respir J 1995; 8: 1488-1493.
10. Pedersen S. Comparing inhaled glucocorticosteroids. Allergy 1999; 54: Suppl. 49, 42-50.
11. Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54: 108-114.
12. Beck-Ripp J, Griese M, Arenz S, Köring C, Pasqualoni B, Bufler P. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J 2002; 19: 1015-1019.
13. Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone diskus and budesonide turbuhaler. Am J Respir Crit Care Med 2003; 168: 779-782.
14. Wildhaber JH, Devadason SG, Wilson JM, et al. Lung deposition of budesonide from turbuhaler in asthmatic children. Eur J Pediatr 1998; 157: 1017-1022.
15. Devadason SG, Huang T, Walker S, Troedson R, Le Souef PN. Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children. Eur Respir J 2003; 21: 1007-1011.
16. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7: 1839-1844.
17. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346-1353.
18. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone. Chest 2002; 122: 510-516.
19. Devadason SG, Everard ML, MacEarlan C, et al. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 1997; 10: 2023-2028.
20. Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52: 529-538.
21. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia, W.B. Saunders Co., 1971; pp. 170-180, 254.
22. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J 1997; 10: 1683-1693.
23. Hofstra WB, Sont JK, Sterk PJ, Neijens HJ, Kuethe MC, Duiverman EJ. Sample size estimation in studies monitoring exercise-induced bronchoconstriction in asthmatic children. Thorax 1997; 52: 739-741.
24. Soria I, Harrison LI, Machacek JH, Cline AC, Stampone PA. Beclomethasone relative availability of oral versus inhaled beclomethasone dipropionate from an HFA-134a metered dose inhaler. Biopharm Drug Dispos 1998; 19: 297-302.
25. Worth H, Muir JF, Pieters WR. Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. Respiration 2001; 68: 517-526.
26. Reichel W, Dahl R, Ringdal N, Zetterstrom O, van den Elshout FJ, Laitinen LA. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int J Clin Pract 2001; 55: 100-106.
27. Nayak A, Lanier R, Weinstein S, Stampone P, Welch M. Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma: a 12-week, randomized, double-blind, placebo-controlled study. Chest 2002; 122: 1956-1965 (Erratum in: Chest 2003; 123: 2164).
28. Szefler SJ, Warner J, Staab D, et al. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open-label, randomized trial. J Allergy Clin Immunol 2002; 110: 45-50.
29. Farmer IS, Middle M, Savic J, Perri VL, Herdman MJ. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma. Respir Med 2000; 94: 57-63.
30. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998; 132: 976-982.